Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
Date:2/10/2011

specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists.  Auxilium markets XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a testosterone gel, for the topical treatment of hypogonadism.  Auxilium has two projects in clinical development.  XIAFLEX is in phase III of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis).  Auxilium also has rights to pursue additional indications for XIAFLEX.  For additional information, visit http://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

In addition to historical facts or statements of current condition, this release contains forward-looking statements within the meaning of the "Safe Harbor" provisions of The Private Securities Litigation Reform Act of 1995, including statements regarding

  • Auxilium's expected financial performance during 2011, including XIAFLEX revenues, Testim revenues, research and development spending, selling, general and administrative expenses, stock-based compensation expenses and net loss;
  • Auxilium's strategic priorities for 2011;
  • the Company's likelihood of becoming a rapidly growing,  profitable and sustainable  biopharmaceutical company;
  • the market size for XIAFLEX and its potential to be a blockbuster opportunity that could provide sustainable long-term growth for the Company;
  • EMA approval of Xiapex in 2011;
  • the extent and duration of patent protection for X
    '/>"/>

  • SOURCE Auxilium Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
    2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
    3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
    4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
    5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
    6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
    7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
    8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
    9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
    10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
    11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
    (Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
    (Date:1/15/2014)... assembling a club sandwich at the nanoscale, National ... succeeded in crafting a uniform, multi-walled carbon-nanotube-based coating ... used in upholstered furniture and other soft furnishings. ... was reduced 35 percent compared with untreated foam. ...
    (Date:1/15/2014)... Jan. 15, 2014   Niagara Thermal Products is ... Buffalo BioBlower Technologies LLC ("B3") as the critical thermal ... award from the Army Corps of Engineers.  B3 has ... all biological contaminants and destroys VOCs and other chemical ...
    Breaking Biology Technology:Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2Niagara Thermal Products LLC Selected as Critical Supplier for Buffalo BioBlower Air Purification Systems 2
    ... from Phase II Study Shows 71% Objective Tumor Response Rate ... , - Secondary Endpoint Evaluation Shows Promising 7.4 Month Median ... , ORLANDO, Fla. and TUSTIN, Calif., June 1 Peregrine ... preliminary results from a Phase II trial of its lead ...
    ... UCB, Inc. and the Crohn,s Disease Working Group (CDWG) today ... Inflammatory Bowel Disease (IBD) for Gastroenterology (GI) Fellows, who each ... or basic research, totaling $175,000 for all four grants. The ... awards were funded by a grant from UCB. A ...
    ... Therapeutics announced today that promising results from ongoing clinical studies ... presented on AT-101, an oral, pan-Bcl-2 inhibitor, at the 2009 ... 2, in Orlando, Florida. , , (Logo: ... , , "We are delighted with the depth ...
    Cached Biology Technology:Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 2Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 3Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 4Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 5Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting 6UCB and Crohn's Disease Working Group Award $175,000 in Research Grants to Gastroenterology Fellows 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 2Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 3Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 4Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting 5
    (Date:7/10/2014)... Institute for Basic Science (IBS), the main organization of ... Korea, has announced that a group of researchers, led ... technology in the field of optogenetics that can remotely ... new technology "OptoTrk" and it has succeeded with neuronal ... technology is that it requires only light to activate ...
    (Date:7/10/2014)... soap might not be ape friendly, and the situation appears ... the Cell Press journal Current Biology on July ... led to the conversion of Southeast Asian forest into oil ... are not put in place very soon, researchers say the ... will be bad news for great apes there as well. ...
    (Date:7/10/2014)... Imagine the open ocean as a microbial megacity, teeming ... drop of water, hundreds of types of bacteria can ... of these ocean microbes have their own daily cyclesnot ... to wake up, commute, work, and eat at the ... sun. Light-loving photoautotrophsbacteria that need solar energy to help ...
    Breaking Biology News(10 mins):New optogenetic tool for controlling neuronal signalling by blue light 2Hunger for vegetable oil means trouble for Africa's great apes 2New research finds ocean's most abundant organisms have clear daily cycles 2New research finds ocean's most abundant organisms have clear daily cycles 3
    ... Pop Quiz: what creatures make up more than 70% ... and have long served as model organisms in many ... To begin exploring this question, a new ... was formed and held its inaugural workshop at Nova ...
    ... are sensitive to social influences but they maintain their ... to what the majority of group members are doing. ... obtain greater rewards, MPI researchers found. ... a rich palette of learning behaviour, both individually and ...
    ... (UH) Case Medical Center Seidman Cancer Center and Case ... how changes in the genetic composition of breast cancer ... chemotherapy can predict future clinical outcomes in patients. ... reduction in the most commonly mutated genes in breast ...
    Cached Biology News:New organization brings together top researchers to sequence genomes of invertebrates 2New organization brings together top researchers to sequence genomes of invertebrates 3Chimpanzees are rational, not conformists 2Deep sequencing of breast cancer tumors to predict clinical outcomes after single dose of therapy 2
    ...
    Jak3 Antibody Ship: Hot Store: -20 C...
    WASF2 Immunogen: WASF2 (NP_008921, 73 a.a. ~ 173 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
    Applications: Western blotting Stability: Room temperature, indefinitely ...
    Biology Products: